{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:02:26Z","timestamp":1785268946434,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82151320"],"award-info":[{"award-number":["82151320"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the National Natural Science Foundation General Project","award":["81970639"],"award-info":[{"award-number":["81970639"]}]},{"name":"the Scientific Research Project of Jiangsu Provincial Health and Wellness Commission","award":["H2017023"],"award-info":[{"award-number":["H2017023"]}]},{"name":"the Priority Academic Program Development of Jiangsu Higher Education Institutions"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00432-022-04437-9","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T11:06:34Z","timestamp":1667473594000},"page":"5061-5070","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study"],"prefix":"10.1007","volume":"149","author":[{"given":"Kang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongke","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changying","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"4437_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004421","author":"ML Baker","year":"2022","unstructured":"Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N et al (2022) Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-004421","journal-title":"J Immunother Cancer"},{"key":"4437_CR2","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"key":"4437_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"key":"4437_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JOP.18.00005","volume":"14","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Thompson JA (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline summary. J Oncol Pract 14:247\u2013249. https:\/\/doi.org\/10.1200\/JOP.18.00005","journal-title":"J Oncol Pract"},{"key":"4437_CR5","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M et al (2017) First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 376:2415\u20132426. https:\/\/doi.org\/10.1056\/NEJMoa1613493","journal-title":"N Engl J Med"},{"key":"4437_CR6","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR et al (2016) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90:638\u2013647. https:\/\/doi.org\/10.1016\/j.kint.2016.04.008","journal-title":"Kidney Int"},{"key":"4437_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","volume":"31","author":"FB Cortazar","year":"2020","unstructured":"Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS et al (2020) Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol 31:435\u2013446. https:\/\/doi.org\/10.1681\/ASN.2019070676","journal-title":"J Am Soc Nephrol"},{"key":"4437_CR8","doi-asserted-by":"publisher","first-page":"703893","DOI":"10.3389\/fonc.2021.703893","volume":"11","author":"L Daniello","year":"2021","unstructured":"Daniello L, Elshiaty M, Bozorgmehr F, Kuon J, Kazdal D, Schindler H et al (2021) Therapeutic and prognostic implications of immune-related adverse events in advanced non-small-cell lung cancer. Front Oncol 11:703893. https:\/\/doi.org\/10.3389\/fonc.2021.703893","journal-title":"Front Oncol"},{"key":"4437_CR9","doi-asserted-by":"publisher","first-page":"e0195945","DOI":"10.1371\/journal.pone.0195945","volume":"13","author":"C Dumenil","year":"2018","unstructured":"Dumenil C, Massiani MA, Dumoulin J, Giraud V, Labrune S, Chinet T et al (2018) Clinical factors associated with early progression and grade 3\u20134 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab. PLoS ONE 13:e0195945. https:\/\/doi.org\/10.1371\/journal.pone.0195945","journal-title":"PLoS ONE"},{"key":"4437_CR10","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.jtho.2020.04.021","volume":"15","author":"DW Dumoulin","year":"2020","unstructured":"Dumoulin DW, Visser S, Cornelissen R, van Gelder T, Vansteenkiste J, von der Thusen J et al (2020) Renal toxicity from pemetrexed and pembrolizumab in the era of combination therapy in patients with metastatic nonsquamous cell NSCLC. J Thorac Oncol 15:1472\u20131483. https:\/\/doi.org\/10.1016\/j.jtho.2020.04.021","journal-title":"J Thorac Oncol"},{"key":"4437_CR11","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:1837\u20131846. https:\/\/doi.org\/10.1016\/S0140-6736(16)00587-0","journal-title":"Lancet"},{"key":"4437_CR12","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"4437_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.34067\/KID.0000852019","volume":"1","author":"S Gupta","year":"2020","unstructured":"Gupta S, Cortazar FB, Riella LV, Leaf DE (2020) Immune checkpoint inhibitor nephrotoxicity: update 2020. Kidney360 1:130\u2013140. https:\/\/doi.org\/10.34067\/KID.0000852019","journal-title":"Kidney360"},{"key":"4437_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003467","author":"S Gupta","year":"2021","unstructured":"Gupta S, Short SAP, Sise ME, Prosek JM, Madhavan SM, Soler MJ et al (2021) Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-003467","journal-title":"J Immunother Cancer"},{"key":"4437_CR15","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540\u20131550. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet"},{"key":"4437_CR16","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379:2220\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa1809064","journal-title":"N Engl J Med"},{"key":"4437_CR17","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120:c179\u2013c184. https:\/\/doi.org\/10.1159\/000339789","journal-title":"Nephron Clin Pract"},{"key":"4437_CR18","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1053\/j.ajkd.2010.02.337","volume":"55","author":"AS Levey","year":"2010","unstructured":"Levey AS, Stevens LA (2010) Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 55:622\u2013627. https:\/\/doi.org\/10.1053\/j.ajkd.2010.02.337","journal-title":"Am J Kidney Dis"},{"key":"4437_CR19","doi-asserted-by":"publisher","first-page":"662731","DOI":"10.3389\/fonc.2021.662731","volume":"11","author":"K Liu","year":"2021","unstructured":"Liu K, Qin Z, Xu X, Li T, Ge Y, Mao H et al (2021) Comparative risk of renal adverse events in patients receiving immune checkpoint inhibitors: a Bayesian network meta-analysis. Front Oncol 11:662731. https:\/\/doi.org\/10.3389\/fonc.2021.662731","journal-title":"Front Oncol"},{"key":"4437_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/ndt\/gfy105","volume":"34","author":"S Manohar","year":"2019","unstructured":"Manohar S, Kompotiatis P, Thongprayoon C, Cheungpasitporn W, Herrmann J, Herrmann SM (2019) Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrol Dial Transplant 34:108\u2013117. https:\/\/doi.org\/10.1093\/ndt\/gfy105","journal-title":"Nephrol Dial Transplant"},{"key":"4437_CR21","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563\u2013580. https:\/\/doi.org\/10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"key":"4437_CR22","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393:1819\u20131830. https:\/\/doi.org\/10.1016\/S0140-6736(18)32409-7","journal-title":"Lancet"},{"key":"4437_CR23","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J et al (2018) Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379:2040\u20132051. https:\/\/doi.org\/10.1056\/NEJMoa1810865","journal-title":"N Engl J Med"},{"key":"4437_CR24","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2215\/CJN.02780312","volume":"7","author":"MA Perazella","year":"2012","unstructured":"Perazella MA (2012) Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol 7:1713\u20131721. https:\/\/doi.org\/10.2215\/CJN.02780312","journal-title":"Clin J Am Soc Nephrol"},{"key":"4437_CR25","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.2217\/fon-2021-1004","volume":"18","author":"Z Qin","year":"2022","unstructured":"Qin Z, Liu K, Xu X, Li T, Ge Y, Wu B et al (2022) Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors. Future Oncol 18:1951\u20131962. https:\/\/doi.org\/10.2217\/fon-2021-1004","journal-title":"Future Oncol"},{"key":"4437_CR26","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1056\/NEJMra1703413","volume":"377","author":"M Reck","year":"2017","unstructured":"Reck M, Rabe KF (2017) Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med 377:849\u2013861. https:\/\/doi.org\/10.1056\/NEJMra1703413","journal-title":"N Engl J Med"},{"key":"4437_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255\u2013265. https:\/\/doi.org\/10.1016\/S0140-6736(16)32517-X","journal-title":"Lancet"},{"key":"4437_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","volume":"16","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ et al (2015) Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16:257\u2013265. https:\/\/doi.org\/10.1016\/S1470-2045(15)70054-9","journal-title":"Lancet Oncol"},{"key":"4437_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92\u201398. https:\/\/doi.org\/10.1056\/NEJMoa011954","journal-title":"N Engl J Med"},{"key":"4437_CR30","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.00990119","volume":"14","author":"H Seethapathy","year":"2019","unstructured":"Seethapathy H, Zhao S, Chute DF, Zubiri L, Oppong Y, Strohbehn I et al (2019) The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol 14:1692\u20131700. https:\/\/doi.org\/10.2215\/CJN.00990119","journal-title":"Clin J Am Soc Nephrol"},{"key":"4437_CR31","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/1759-7714.14274","volume":"13","author":"Y Shi","year":"2022","unstructured":"Shi Y, Fang J, Zhou C, Liu A, Wang Y, Meng Q et al (2022) Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China. Thorac Cancer 13:412\u2013422. https:\/\/doi.org\/10.1111\/1759-7714.14274","journal-title":"Thorac Cancer"},{"key":"4437_CR32","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378:2288\u20132301. https:\/\/doi.org\/10.1056\/NEJMoa1716948","journal-title":"N Engl J Med"},{"key":"4437_CR33","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/ndt\/gfaa137","volume":"36","author":"C Stein","year":"2021","unstructured":"Stein C, Burtey S, Mancini J, Pelletier M, Sallee M, Brunet P et al (2021) Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. Nephrol Dial Transplant 36:1664\u20131674. https:\/\/doi.org\/10.1093\/ndt\/gfaa137","journal-title":"Nephrol Dial Transplant"},{"key":"4437_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"4437_CR35","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","volume":"45","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C et al (2017) Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol 45:160\u2013169. https:\/\/doi.org\/10.1159\/000455014","journal-title":"Am J Nephrol"},{"key":"4437_CR36","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrd1691","volume":"4","author":"D Wang","year":"2005","unstructured":"Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307\u2013320. https:\/\/doi.org\/10.1038\/nrd1691","journal-title":"Nat Rev Drug Discov"},{"key":"4437_CR37","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1002\/ijc.31012","volume":"141","author":"Y Wu","year":"2017","unstructured":"Wu Y, Shi H, Jiang M, Qiu M, Jia K, Cao T et al (2017) The clinical value of combination of immune checkpoint inhibitors in cancer patients: a meta-analysis of efficacy and safety. Int J Cancer 141:2562\u20132570. https:\/\/doi.org\/10.1002\/ijc.31012","journal-title":"Int J Cancer"},{"key":"4437_CR38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.21037\/atm-21-6899","volume":"10","author":"X Zheng","year":"2022","unstructured":"Zheng X, Tao G, Sun S, Jin X, Chen Y, Zhang Y et al (2022) Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world study. Ann Transl Med 10:183. https:\/\/doi.org\/10.21037\/atm-21-6899","journal-title":"Ann Transl Med"},{"key":"4437_CR39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s40425-018-0477-9","volume":"6","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Chen C, Zhang X, Fu S, Xue C, Ma Y et al (2018) Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis. J Immunother Cancer 6:155. https:\/\/doi.org\/10.1186\/s40425-018-0477-9","journal-title":"J Immunother Cancer"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04437-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04437-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04437-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T14:16:23Z","timestamp":1689430583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04437-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4437"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04437-9","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,3]]},"assertion":[{"value":"5 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study followed the principles of the Declaration of Helsinki and was approved by the ethical research committee of the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital; 2020-SR-107).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}